OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
The first MASH drug therapy on the horizon: Current perspectives of resmetirom
Salvatore Petta, Giovanni Targher, Stefano Romeo, et al.
Liver International (2024) Vol. 44, Iss. 7, pp. 1526-1536
Open Access | Times Cited: 63
Salvatore Petta, Giovanni Targher, Stefano Romeo, et al.
Liver International (2024) Vol. 44, Iss. 7, pp. 1526-1536
Open Access | Times Cited: 63
Showing 1-25 of 63 citing articles:
Global burden of metabolic diseases, 1990–2021
Huai Zhang, Xiaodong Zhou, Michael D. Shapiro, et al.
Metabolism (2024) Vol. 160, pp. 155999-155999
Closed Access | Times Cited: 74
Huai Zhang, Xiaodong Zhou, Michael D. Shapiro, et al.
Metabolism (2024) Vol. 160, pp. 155999-155999
Closed Access | Times Cited: 74
Sexual dimorphism of metabolic dysfunction-associated steatotic liver disease
Alessandro Cherubini, Sara Della Torre, Serena Pelusi, et al.
Trends in Molecular Medicine (2024)
Closed Access | Times Cited: 20
Alessandro Cherubini, Sara Della Torre, Serena Pelusi, et al.
Trends in Molecular Medicine (2024)
Closed Access | Times Cited: 20
Thyromimetics and MASLD: Unveiling the Novel Molecules Beyond Resmetirom
Devaraj Ezhilarasan
Journal of Gastroenterology and Hepatology (2025)
Closed Access | Times Cited: 2
Devaraj Ezhilarasan
Journal of Gastroenterology and Hepatology (2025)
Closed Access | Times Cited: 2
Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis
Arun George Devasia, Adaikalavan Ramasamy, Chen Huei Leo
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1778-1778
Open Access | Times Cited: 2
Arun George Devasia, Adaikalavan Ramasamy, Chen Huei Leo
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1778-1778
Open Access | Times Cited: 2
An overview of obesity‐related complications: The epidemiological evidence linking body weight and other markers of obesity to adverse health outcomes
Matthias Blüher
Diabetes Obesity and Metabolism (2025)
Open Access | Times Cited: 2
Matthias Blüher
Diabetes Obesity and Metabolism (2025)
Open Access | Times Cited: 2
Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review
Haixiang Zheng, Leonardo A. Sechi, Eliano Pio Navarese, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 14
Haixiang Zheng, Leonardo A. Sechi, Eliano Pio Navarese, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 14
Comparative efficacy of THR-β agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and Pan-PPAR agonists for MASLD: A systematic review and network meta-analysis
Rutao Lin, Qinmei Sun, Xin Xin, et al.
Metabolism (2024) Vol. 161, pp. 156043-156043
Closed Access | Times Cited: 9
Rutao Lin, Qinmei Sun, Xin Xin, et al.
Metabolism (2024) Vol. 161, pp. 156043-156043
Closed Access | Times Cited: 9
Mitochondrial targeted therapy in MAFLD
Sien Lai, Dongsheng Tang, Juan Feng
Biochemical and Biophysical Research Communications (2025) Vol. 753, pp. 151498-151498
Closed Access | Times Cited: 1
Sien Lai, Dongsheng Tang, Juan Feng
Biochemical and Biophysical Research Communications (2025) Vol. 753, pp. 151498-151498
Closed Access | Times Cited: 1
Risk of Serious Bacterial and Non‐Bacterial Infections in People With MASLD
Giovanni Targher, Herbert Tilg, Luca Valenti
Liver International (2025) Vol. 45, Iss. 4
Open Access | Times Cited: 1
Giovanni Targher, Herbert Tilg, Luca Valenti
Liver International (2025) Vol. 45, Iss. 4
Open Access | Times Cited: 1
Recompensation in MASLD-related cirrhosis via metabolic bariatric surgery
Gong Feng, Yu Han, Wah Yang, et al.
Trends in Endocrinology and Metabolism (2024)
Closed Access | Times Cited: 7
Gong Feng, Yu Han, Wah Yang, et al.
Trends in Endocrinology and Metabolism (2024)
Closed Access | Times Cited: 7
The Role of PNPLA3_rs738409 Gene Variant, Lifestyle Factors, and Bioactive Compounds in Nonalcoholic Fatty Liver Disease: A Population-Based and Molecular Approach towards Healthy Nutrition
Meiling Liu, Sunmin Park
Nutrients (2024) Vol. 16, Iss. 8, pp. 1239-1239
Open Access | Times Cited: 6
Meiling Liu, Sunmin Park
Nutrients (2024) Vol. 16, Iss. 8, pp. 1239-1239
Open Access | Times Cited: 6
Evaluation of ChatGPT as a Counselling Tool for Italian-Speaking MASLD Patients: Assessment of Accuracy, Completeness and Comprehensibility
Nicola Pugliese, Davide Polverini, Rosa Lombardi, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 6, pp. 568-568
Open Access | Times Cited: 6
Nicola Pugliese, Davide Polverini, Rosa Lombardi, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 6, pp. 568-568
Open Access | Times Cited: 6
Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Amani Elshaer, David M. Chascsa, Blanca Lizaola‐Mayo
Life (2024) Vol. 14, Iss. 7, pp. 844-844
Open Access | Times Cited: 6
Amani Elshaer, David M. Chascsa, Blanca Lizaola‐Mayo
Life (2024) Vol. 14, Iss. 7, pp. 844-844
Open Access | Times Cited: 6
Global Trends and Inequalities of Liver Complications Related to Metabolic Dysfunction‐Associated Steatotic Liver Disease: An Analysis From 1990 to 2021
Fang Lü, Jinli Liu, Bingyang She, et al.
Liver International (2024)
Open Access | Times Cited: 5
Fang Lü, Jinli Liu, Bingyang She, et al.
Liver International (2024)
Open Access | Times Cited: 5
Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists
Giovanni Targher, Alessandro Mantovani, Christopher D. Byrne, et al.
Gut (2024), pp. gutjnl-334023
Closed Access | Times Cited: 4
Giovanni Targher, Alessandro Mantovani, Christopher D. Byrne, et al.
Gut (2024), pp. gutjnl-334023
Closed Access | Times Cited: 4
Extracellular vesicle-mediated approaches for the diagnosis and therapy of MASLD: current advances and future prospective
Swasthika Gurjar, R. A., Raghavendra Upadhya, et al.
Lipids in Health and Disease (2025) Vol. 24, Iss. 1
Open Access
Swasthika Gurjar, R. A., Raghavendra Upadhya, et al.
Lipids in Health and Disease (2025) Vol. 24, Iss. 1
Open Access
USP25 directly interacts with and deubiquitinates PPARα to increase PPARα stability in hepatocytes and attenuate high-fat diet-induced MASLD in mice
Leiming Jin, Weiwei Zhu, Xiang Hu, et al.
Cell Death and Differentiation (2025)
Closed Access
Leiming Jin, Weiwei Zhu, Xiang Hu, et al.
Cell Death and Differentiation (2025)
Closed Access
Comparison of resmetirom quantative analysis in API and formulation models based on PXRD, FTIR and Raman scanning imaging combined with univariate and multivariate analyses
Chen Yang, Ying Luo, Weiling Sun, et al.
Talanta (2025), pp. 127568-127568
Closed Access
Chen Yang, Ying Luo, Weiling Sun, et al.
Talanta (2025), pp. 127568-127568
Closed Access
Ethanol extract of Polygonatum cyrtonema Hua mitigates non-alcoholic steatohepatitis in mice
Dongliang Chen, Yue Shen, Fang Huang, et al.
Frontiers in Pharmacology (2025) Vol. 15
Open Access
Dongliang Chen, Yue Shen, Fang Huang, et al.
Frontiers in Pharmacology (2025) Vol. 15
Open Access
The Global Burden of Cirrhosis and Other Chronic Liver Diseases in 2021
Ethan Kai Jun Tham, Darren Jun Hao Tan, Pojsakorn Danpanichkul, et al.
Liver International (2025) Vol. 45, Iss. 3
Open Access
Ethan Kai Jun Tham, Darren Jun Hao Tan, Pojsakorn Danpanichkul, et al.
Liver International (2025) Vol. 45, Iss. 3
Open Access
Resmetirom for Moderate to Advanced Liver Fibrosis
Devada Singh-Franco, Melissa Santibañez, Huy Quang Pham, et al.
The Journal for Nurse Practitioners (2025), pp. 105330-105330
Closed Access
Devada Singh-Franco, Melissa Santibañez, Huy Quang Pham, et al.
The Journal for Nurse Practitioners (2025), pp. 105330-105330
Closed Access
Altered liver sinusoidal endothelial cells in MASLD and their evolution following lanifibranor treatment
Pierre‐Emmanuel Rautou, Shivani Chotkoe, Louise Biquard, et al.
JHEP Reports (2025), pp. 101366-101366
Open Access
Pierre‐Emmanuel Rautou, Shivani Chotkoe, Louise Biquard, et al.
JHEP Reports (2025), pp. 101366-101366
Open Access
d4-Cystamine: A Deuterated Cystamine Derivative with Improved Anti-Inflammatory and Anti-Fibrotic Activities in a Murine Model of Fibrosing Steatohepatitis
Aleksandra Leszczynska, Thibault Alle, Benedikt Kaufmann, et al.
ACS Pharmacology & Translational Science (2025) Vol. 8, Iss. 3, pp. 885-898
Open Access
Aleksandra Leszczynska, Thibault Alle, Benedikt Kaufmann, et al.
ACS Pharmacology & Translational Science (2025) Vol. 8, Iss. 3, pp. 885-898
Open Access
Drug Pipeline for MASLD: What Can Be Learned from the Successful Story of Resmetirom
Elizabeta Knezović, Marija Hefer, Suzana Blažanović, et al.
Current Issues in Molecular Biology (2025) Vol. 47, Iss. 3, pp. 154-154
Open Access
Elizabeta Knezović, Marija Hefer, Suzana Blažanović, et al.
Current Issues in Molecular Biology (2025) Vol. 47, Iss. 3, pp. 154-154
Open Access
Analyzing MASLD interventional clinical trial registration based on the ClinicalTrials.gov database
Hui Du, Jihan Huang, Youhua Wang, et al.
BMC Gastroenterology (2025) Vol. 25, Iss. 1
Open Access
Hui Du, Jihan Huang, Youhua Wang, et al.
BMC Gastroenterology (2025) Vol. 25, Iss. 1
Open Access
